Over the last decade, the immune checkpoint inhibitors (ICIs) targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have shown significant clinical benefit for advanced NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.